In Canada, switching to a one-dose, gender-neutral vaccination program for human papillomavirus (HPV) could use vaccine doses more efficiently and prevent a similar number of cervical cancer cases, ...

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

This study proposes a cross-species transcriptomic framework to predict vaccine reactogenicity, with implications for preclinical vaccine safety assessment. The findings show that mouse muscle ...

Northwestern researchers have shown that when it comes to cancer vaccines, arrangement can be just as important as ingredients. By repositioning a small fragment of an HPV protein on a DNA-based ...

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective ...

Screening for cervical cancer every 15 to 25 years was cost-effective for women vaccinated against HPV between the ages of 12 and 24 years.

The vaccine against human papillomavirus, or HPV, has reduced cervical cancer by nearly 90% in women vaccinated as ...

COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new ...

Evaxion A/S has announced the initiation of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS), a pathogen responsible for a wide range of infections globally, including severe ...